V2 sact_regimen
781,388 rows · 12 columns
| ENCORE_PATIENT_ID | MERGED_REGIMEN_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | BENCHMARK_GROUP | LINK_NUMBER |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 20160321 | 20169877 | 1.6 | 82.5 | Palliative (P) | 2018-01-29 | 2019-08-05 | DARATUMUMAB | 02 | N | CAPECITABINE + OXALIPLATIN + TRASTUZUMAB | 101866424 |
| 20160629 | 20169878 | 1.6 | 83.6 | Palliative (P) | 2021-09-03 | 2021-09-05 | Capecitabine + Streptozocin | 02 | null | CARBOPLATIN + EPIRUBICIN + FLUOROURACIL | 101802734 |
| 20161356 | 20169880 | 1.82 | 79.35 | Palliative (P) | 2017-08-22 | 2017-10-17 | STS Rhabdomyosarcoma RMS 2005 IVADo | 02 | N | MITOMYCIN | 100087950 |
| 20161556 | 20169881 | 1.57 | 78.1 | null | 2018-03-19 | 2018-03-19 | STS Rhabdo VIT0910 Vinc Irinotecan | 02 | N | CAPECITABINE + OXALIPLATIN + TRASTUZUMAB | 101182578 |
| 20163011 | 20169884 | 1.58 | 70 | 03 | 2019-06-27 | 2019-06-30 | COSMIC TRIAL | 02 | N | CYCLOPHOSPHAMIDE + DOXORUBICIN + RITUXIMAB + VINCRISTINE | 100465565 |
| 20164336 | 20169885 | 1.78 | 108 | Curative (C) | null | 2018-10-16 | Bortezomib + CYCLOPHOSPHAMIDE | Y | null | CISPLATIN + FLUOROURACIL + RT | 101712263 |
| 20164782 | 20169886 | 1.55 | 97 | Palliative (P) | 2020-05-03 | 2020-05-03 | DARATUMUMAB | 02 | Y | MPV | 100187380 |
| 20167281 | 20169887 | 1.62 | null | Adjuvant (A) | 2017-07-31 | 2017-08-14 | Vinorelbine (oral) | 02 | N | TRASTUZUMAB EMTANSINE | 101265092 |
| 20167598 | 20169888 | 1.65 | 14.5 | Neo-adjuvant (N) | 2022-02-01 | 2022-03-02 | INTERAACT trial | 2 | null | CYCLOPHOSPHAMIDE + THALIDOMIDE | 100419704 |
| 20167684 | 20169889 | 1.6 | 71.1 | 03 | 2021-03-22 | 2021-03-29 | Hepatoblastoma VHR Block A Cisplatin/Dox | 02 | null | ATEZOLIZUMAB | 100773168 |
| 20168615 | 20169890 | 1.82 | 77.6 | null | 2017-08-27 | 2017-08-27 | CHOP R - 21 days | 2 | N | GEMCARBO | 101279647 |
| 20169092 | 20169891 | 1.75 | 55.85 | Neo-adjuvant (N) | 2018-03-02 | 2018-03-22 | Cisplatin +FU +Trastuzumab - Load | 02 | N | CARBOPLATIN + PEMBROLIZUMAB + PEMETREXED | 100274021 |
| 20170223 | 20169895 | 1.75 | 84.2 | null | 2021-03-22 | 2021-04-05 | FEC 100 | N | N | IRINOTECAN + RALTITREXED | 100854169 |
| 20171067 | 20169897 | 1.95 | 54.7 | null | 2021-05-08 | 2021-05-22 | Bevacizumab + Oxaliplatin +MdG | 02 | N | CYCLOPHOSPHAMIDE + DOXORUBICIN + VINCRISTINE | 101456253 |
| 20171355 | 20169898 | 1.89 | 57.1 | Neo-adjuvant (N) | 2018-05-04 | 2018-05-04 | BORTEZOMIB + THALIDOMIDE | 02 | N | ACELARATE TRIAL | 100547999 |
| 20171611 | 20169899 | 1.71 | 73 | Palliative (P) | 2017-10-02 | 2017-10-02 | Bevacizumab + FLUOROURACIL + IRINOTECAN | 02 | null | MITOMYCIN | 100691231 |
| 20171685 | 20169900 | 1.77 | 117.5 | Neo-adjuvant (N) | 2022-02-09 | 2022-03-12 | POMALIDOMIDE | 02 | null | CARBOPLATIN + VINORELBINE | 100753451 |
| 20172335 | 20169902 | 1.84 | 82 | 03 | 2020-10-29 | 2020-11-01 | Radium 223 | 01 | N | SCOPE2 TRIAL | 101193831 |
| 20172650 | 20169903 | 1.81 | 77.7 | Palliative (P) | 2016-11-22 | 2017-12-12 | DARATUMUMAB | 02 | null | FULVESTRANT + RIBOCICLIB | 100315898 |
| 20173337 | 20169905 | 1.49 | 50.3 | Curative (C) | 2018-09-06 | 2018-09-22 | CISPLATIN + RALTITREXED + Trastuzumab | 02 | null | FLUOROURACIL + LIPOSOMAL IRINOTECAN | 100025739 |
| 20175290 | 20169906 | 1.75 | 57.1 | Palliative (P) | 2019-06-25 | 2019-06-26 | ECarboF | 02 | null | TEMOZOLOMIDE | 101297314 |
| 20175860 | 20169907 | 1.8 | 115.9 | 03 | 2018-10-15 | 2018-10-16 | CAPE + OXALIPLATIN + TRASTUZUMAB | 02 | N | CETUXIMAB + FLUOROURACIL | 101851228 |
| 20176343 | 20169908 | 1.85 | 101.5 | null | 2022-04-03 | 2022-05-17 | CISPLATIN + FLUOROURACIL + RT | 01 | N | CISPLATIN + TEYSUNO | 100305895 |
| 20176672 | 20169909 | 1.48 | 61 | null | 2019-10-06 | 2019-11-04 | null | 02 | N | CAPITAL TRIAL | 100764749 |
| 20176772 | 20169910 | 1.8 | 89.1 | Palliative (P) | 2017-05-05 | 2017-07-29 | Pazopanib | 02 | N | DABRAFENIB + TRAMETINIB | 101801059 |
| 20177553 | 20169913 | 1.82 | 70.1 | Palliative (P) | 2020-06-16 | 2020-06-26 | CISPLATIN + FLUOROURACIL + RT | 02 | null | BEAM | 100565509 |
| 20178873 | 20169915 | 1.65 | 85.3 | Neo-adjuvant (N) | 2016-09-05 | 2016-11-03 | CAP + RT | 02 | null | VINCRISTINE | 100843706 |
| 20180926 | 20169916 | 1.55 | 68.5 | Curative (C) | 2019-09-09 | 2019-11-18 | TOPOTECAN | 02 | N | HEPATOBLASTOMA VHR BLOCK C CARBO (AUC6.6)/DOX | 100350853 |
| 20182177 | 20169918 | 1.53 | 61.6 | 03 | 2019-01-22 | 2019-02-01 | Capecitabine + Streptozocin | 02 | N | FOCUS4 TRIAL | 100068210 |
| 20183306 | 20169921 | 0 | 81.55 | Neo-adjuvant (N) | 2021-04-18 | 2021-06-29 | null | 01 | N | GEMCITABINE + PACLITAXEL | 100379481 |
| 20183463 | 20169922 | null | null | Curative (C) | 2016-12-17 | 2016-12-17 | Amsacrine + FLUOROURACIL + IRINOTECAN + OXALIPLATIN | 01 | N | MITOMYCIN | 101746146 |
| 20184308 | 20169923 | 1.82 | 52.6 | null | 2022-01-20 | 2022-01-20 | EC | 02 | null | TRABECTEDIN | 100669532 |
| 20184496 | 20169924 | 1.86 | 88.2 | null | 2018-10-21 | 2018-10-21 | BCG Intravesical | 02 | N | PHITT D CARBOPLATIN/DOXORUBICIN | 100023712 |
| 20184560 | 20169925 | 1.56 | 70.7 | null | 2019-08-30 | 2019-09-05 | SCOPE 2 TRIAL | 02 | N | CARBOPLATIN + FLUOROURACIL + STREPTOZOCIN | 101540921 |
| 20184820 | 20169926 | 1.84 | 93.3 | null | null | 2016-06-26 | Gemcitabine + Oxaliplatin | 99 | null | CAPECITABINE + IRINOTECAN + PANITUMUMAB | 100129984 |
| 20184976 | 20169927 | 1.58 | 74 | null | 2018-03-20 | 2018-05-23 | BCG Intravesical | 02 | null | RITUXIMAB | 100602943 |
| 20185965 | 20169928 | 1.87 | 28.6 | Disease modification (D) | null | 2021-11-16 | Letrozole + Palbociclib | 01 | N | AXITINIB | 101692704 |
| 20186389 | 20169929 | 1.77 | 96 | null | 2019-12-05 | 2019-12-28 | Doxorubicin 75mg/m2 | 02 | null | BACILLUS CALMETTE-GUERIN | 101404371 |
| 20187184 | 20169930 | 1.69 | 91 | Palliative (P) | 2020-06-03 | 2020-06-14 | DOCETAXEL + GEMCITABINE | 01 | null | MELPHALAN | 101518294 |
| 20188987 | 20169932 | 1.6 | 66.05 | Palliative (P) | 2021-03-29 | 2021-04-18 | Rituximab | N | null | BALLAD TRIAL | 101684297 |
| 20189888 | 20169933 | 1.73 | 115.9 | null | 2017-11-22 | 2017-12-06 | Cisplatin + Docetaxel | 02 | N | PAZOPANIB | 100851622 |
| 20189892 | 20169934 | 1.6 | 46.6 | Adjuvant (A) | 2018-06-12 | 2018-07-16 | Alectinib | 02 | N | CARBOPLATIN + PEMETREXED | 100827881 |
| 20190292 | 20169935 | 1.77 | 78.85 | null | 2021-01-18 | 2021-03-09 | CISPLATIN + TRASTUZUMAB | 02 | null | PALBOCICLIB | 101266166 |
| 20190704 | 20169936 | 1.5 | 81.9 | null | 2019-03-08 | 2019-03-22 | Cabazitaxel | 02 | null | EW EUROEWING 2012 ARM A VAC | 101768149 |
| 20190786 | 20169937 | 1.87 | 84.3 | null | 2019-04-02 | 2019-04-02 | Atezolizumab | 02 | null | CAP + RT | 101626160 |
| 20191722 | 20169938 | 1.65 | 106 | Palliative (P) | 2019-08-03 | 2019-08-10 | CISPLATIN + RALTITREXED | N | N | CYCLOPHOSPHAMIDE + DOXORUBICIN + VINCRISTINE | 100789396 |
| 20192236 | 20169939 | null | null | 03 | 2016-01-23 | 2016-06-05 | Palbociclib | 02 | N | PACLITAXEL + TRASTUZUMAB | 101713994 |
| 20192517 | 20169940 | 1.65 | 11 | Palliative (P) | 2019-10-24 | 2019-11-30 | Hydroxycarbamide | 02 | null | DARATUMUMAB | 100811264 |
| 20192633 | 20169941 | 1.63 | 74 | Palliative (P) | 2018-07-04 | 2018-07-11 | SOTORASIB | 02 | N | HYDROXYCARBAMIDE | 100468754 |
| 20192799 | 20169943 | 1.17 | 58.2 | Palliative (P) | 2018-01-25 | 2018-01-25 | null | 02 | null | CISPLATIN + PEMETREXED | 101216402 |